Literature DB >> 15171733

Different cytokine levels in thrombolysis patients as predictors for clinical outcome.

G Mazzotta1, P Sarchielli, V Caso, M Paciaroni, A Floridi, A Floridi, V Gallai.   

Abstract

Thrombolytic therapy not always improves clinical outcome in ischemic stroke patients. This could cause lymphomonocyte accumulation in the infarcted brain area. These produce an excessive amount of proinflammatory cytokines, such as IL-1 beta, IL-6 and TNF-alfa. The aim of our study was to determine ILs levels in fibrinolytic therapy treated patients, compared with healthy controls and to evaluate if the varying levels can predictors of neurological outcome. Eighteen patients underwent thrombolytic treatment with t-PA within 3 h. Plasma levels of IL-1 beta, IL-6, TNF-alfa and IL-10 were determined by ELISA method before and within 24 h after t-PA infusion and compared with controls. Significantly higher levels of IL-1 beta and Il-6 emerged in stroke patients before treatment compared with the control group (P < 0.05 and 0.04, respectively). Slightly higher plasma levels of TNF-alfa and lower plasma levels of IL-10 were also found at base line in stroke patients. After thrombolytic treatment no significant variations were observed in the levels of TNF-alfa and IL-6, whereas a trend toward lower values for IL-1 beta and higher levels for IL-10 was observed. Positive correlations among the values of IL-6, TNF-alfa and National Institute of Health Stroke Scale (NIHSS) at discharges were observed. A similar correlation with modified Rankin scale score at 3 month was found. Pre-treatment cytokine status seems to influence pre-and long-term clinical outcome. Therefore an investigation into the possible predictor of cytokines seem worthy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15171733     DOI: 10.1111/j.1468-1331.2004.00798.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  31 in total

Review 1.  Inflammatory cytokines in experimental and human stroke.

Authors:  Kate Lykke Lambertsen; Knut Biber; Bente Finsen
Journal:  J Cereb Blood Flow Metab       Date:  2012-06-27       Impact factor: 6.200

Review 2.  Cytokines: their role in stroke and potential use as biomarkers and therapeutic targets.

Authors:  Danielle N Doll; Taura L Barr; James W Simpkins
Journal:  Aging Dis       Date:  2014-10-01       Impact factor: 6.745

3.  Activation of immune responses to brain antigens after stroke.

Authors:  Kyra J Becker
Journal:  J Neurochem       Date:  2012-11       Impact factor: 5.372

4.  Functional improvement and immune-inflammatory cytokines profile of ischaemic stroke patients after treatment with boswellic acids: a randomized, double-blind, placebo-controlled, pilot trial.

Authors:  Somayeh Mahmoodi Baram; Saeed Karima; Somayeh Shateri; Abbas Tafakhori; Akbar Fotouhi; Behnam Safarpour Lima; Shima Rajaei; Meisam Mahdavi; Hessam Sepasi Tehrani; Vajiheh Aghamollaii; Seyed Hossein Aghamiri; Behnam Mansouri; Sina Gharahje; Samaneh Kabiri; Maryamosadat Hosseinizadeh; Shima Zare Shahamati; Amir Taher Alborzi
Journal:  Inflammopharmacology       Date:  2019-08-12       Impact factor: 4.473

5.  Plasma proinflammatory and anti-inflammatory cytokine and catecholamine concentrations as predictors of neurological outcome in acute stroke patients.

Authors:  Jun Oto; Atsuhiko Suzue; Daisuke Inui; Yasushi Fukuta; Kikumi Hosotsubo; Mayumi Torii; Shinji Nagahiro; Masaji Nishimura
Journal:  J Anesth       Date:  2008-08-07       Impact factor: 2.078

6.  Evaluation of the inflammatory response in sera from acute ischemic stroke patients by measurement of IL-2 and IL-10.

Authors:  Amit R Nayak; Rajpal S Kashyap; Hemant J Purohit; Dinesh Kabra; Girdhar M Taori; Hatim F Daginawala
Journal:  Inflamm Res       Date:  2009-04-02       Impact factor: 4.575

7.  Inflammatory mechanisms involved in brain injury following cardiac arrest and cardiopulmonary resuscitation.

Authors:  Yanxiao Xiang; Hua Zhao; Jiali Wang; Luetao Zhang; Anchang Liu; Yuguo Chen
Journal:  Biomed Rep       Date:  2016-05-16

8.  Genetic ablation of soluble tumor necrosis factor with preservation of membrane tumor necrosis factor is associated with neuroprotection after focal cerebral ischemia.

Authors:  Pernille M Madsen; Bettina H Clausen; Matilda Degn; Stine Thyssen; Lotte K Kristensen; Martina Svensson; Nicholas Ditzel; Bente Finsen; Tomas Deierborg; Roberta Brambilla; Kate L Lambertsen
Journal:  J Cereb Blood Flow Metab       Date:  2015-10-19       Impact factor: 6.200

9.  Interleukin-1beta augments angiogenic responses of murine endothelial progenitor cells in vitro.

Authors:  Anna Rosell; Ken Arai; Josephine Lok; Tongrong He; Shuzhen Guo; Miriam Navarro; Joan Montaner; Zvonimir S Katusic; Eng H Lo
Journal:  J Cereb Blood Flow Metab       Date:  2009-02-25       Impact factor: 6.200

Review 10.  Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6.

Authors:  William Whiteley; Caroline Jackson; Steff Lewis; Gordon Lowe; Ann Rumley; Peter Sandercock; Joanna Wardlaw; Martin Dennis; Cathie Sudlow
Journal:  PLoS Med       Date:  2009-09-08       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.